Cosmos Health Eyes $24M Doc Pharma Acquisition to Expand European Manufacturing Footprint — Cosmos Health Inc.

Event summary

Cosmos Health signs non-binding LOI to acquire 100% of Doc Pharma S.A., a European GMP pharmaceutical manufacturer with $24M in assets.
Target brings $6.7M in average annual revenue and $3.2M in gross profit over the past three years.
Doc Pharma operates a 59,000 sq. ft. GMP-licensed facility with certifications including ISO, Kosher, and Halal.
Acquisition expected to be immediately accretive, boosting Cosmos Health's production capacity and product portfolio.
Transaction subject to independent director review, fairness opinion, PCAOB audit, and shareholder approval.

The big picture

This acquisition represents Cosmos Health's latest move to build a vertically integrated healthcare platform, following its entry into telehealth through the ZipDoctor acquisition. The deal underscores the strategic importance of in-house manufacturing capabilities in the pharmaceutical sector, particularly for companies looking to control costs and expand margins. With Doc Pharma's European certifications and registrations in key Middle Eastern markets, the acquisition also positions Cosmos Health to strengthen its international distribution network.

What we're watching

Integration Challenges: How Cosmos Health will manage the operational integration of Doc Pharma's European facility with its existing global platform.
Regulatory Scrutiny: Whether the related-party nature of the transaction will draw additional regulatory or shareholder scrutiny.
Execution Risk: The pace at which Cosmos Health can realize the expected synergies and margin improvements from the acquisition.